WHO APPROVES HEPATITIS B VACCINE MADE BY INDIA'S PANACEA
India-based Panacea Biotec has received prequalification accreditation from the World Health Organization (WHO) to supply its recombinant hepatitis B vaccine to U.N. agencies.
Hepatitis B immunization helps prevent chronic hepatitis B virus infection and its consequences, including liver cirrhosis and hepatocellular cancer, the company said.
The overall estimated market for the vaccine for 2007 is around 158 million doses, and is estimated to be 185 million doses in 2008 and 888 million doses in 2009. That would amount to approximately $270 million in 2007, $390 million in 2008 and $1 billion in 2009.